Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Business Wire
JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a 40% reduction in risk of death, whereas Signatera-negative patients derived no significant benefit AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year.CALGB (Alliance)/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with stage III colorectal cancer (CRC). The pre-specified post-hoc analysis included 940 patients with available post-surgical plasma samples, who were randomized to receive FOLFOX +/- celecoxib, a non-steroidal a
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy OutcomesBusiness Wire
- Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards [Seeking Alpha]Seeking Alpha
- Natera Submits Signatera™ CDx PMA to FDABusiness Wire
- A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]Yahoo! Finance
- Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart TransplantationBusiness Wire
NTRA
Earnings
- 11/6/25 - Miss
NTRA
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- NTRA's page on the SEC website